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Background: Follistatin-like 1 (FSTL1) plays both pro-inflammatory and anti-inflammatory roles in the inflammatory processes.We
investigated whether serum FSTL1 could predict the current anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)-
specific indices.
Methods:We randomly selected 74 patients with AAV from a prospective and observational cohort of Korean patients with AAV.
Clinical and laboratory data and AAV-specific indices were recorded. FSTL1 concentration was determined using the stored sera.
The lowest tertile of the short-form 36-item health survey (SF-36) was defined as the current low SF-36. The cutoffs of serum FSTL1
for the current low SF-36 physical component summary (PCS) and SF-36 mental component summary (MCS) were extrapolated by
the receiver operator characteristic curve.
Results: The median age was 62.5 years (55.4% were women). Serum FSTL1 was significantly correlated with SF-36 PCS
(r=  0.374), SF-36MCS (r=0.377), and C-reactive protein (CRP) (r= 0.307), but not with Birmingham vasculitis activity score
(BVAS). In the multivariable linear regression analyses, BVAS, CRP, and serum FSTL1 were independently associated with the
current SF-36 PCS (b=0.255, b=0.430, and b=0.266, respectively) and the current SF-36 MCS (b=0.234, b=0.229,
and b=0.296, respectively). Patients with serum FSTL1 ≥779.8 pg/mL and those with serum FSTL1 ≥841.6 pg/mL exhibited a
significantly higher risk of having the current low SF-36 PCS and SF-36 MCS than those without (relative risk 7.583 and 6.200,
respectively).
Conclusion: Serum FSTL1 could predict the current functional status in AAV patients.
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Systemic vasculitides are categorized by the size of affected
vessels into large, medium, small, and variable vessel
vasculitis. According to the presence of immune complex
in tissue pathology, small vessel vasculitis (SVV) is further
divided into immune complex SVV and anti-neutrophil
cytoplasmic antibody (ANCA)-associated vasculitis
(AAV); AAV affects capillaries, venules, arterioles, and
small arteries and is characterized by necrotizing vasculitis
with few or no deposit of immune complexes based on the
2012 Revised International Chapel Hill Consensus
Conference Nomenclature of Vasculitides.[1] Furthermore,
AAV is composed of three subtypes, namely microscopicAccess this article online




1168polyangiitis (MPA), granulomatosis with polyangiitis
(GPA), and eosinophilic GPA (EGPA).[1,2]
In our cohort of AAV patients, we usually collect AAV-
specific indices at every 3- to 6-month visit: Birmingham
vasculitis activity score (BVAS, version 3) and five-factor
score (FFS) are calculated for assessing the current activity
and the prognosis, respectively;[3,4] vasculitis damage
index (VDI) is evaluated for estimating the current extent
of organ damage;[5] and the Korean version of the short-
form 36-item health survey physical and mental compo-
nent summaries (SF-36 PCS and SF-36 MCS) is collected
for predicting the current functional status.[6] In particular,
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BVAS, FFS, and VDI are primarily completed by
physicians, whereas SF-36 PCS and SF-36 MCS are
mainly recorded by patients. To date, several studies on the
discovery of biomarkers predicting AAV-specific indices,
especially those related to the pathogenesis of AAV have
been conducted. Biomarkers can predict AAV-specific
indices quickly and easily even in difficult situations such as
poor mental or physical states and a new concept of AAV
pathogenesis can also be established by them. Therefore,
the demand for biomarkers is constantly increasing.
Follistatin-like 1 (FSTL1), a bone morphogenetic protein-4
binding protein, is known to be associated with the
development of several organs.[7,8] In addition, FSTL1 has
been reported to play a dual and opposing regulatory role
in the inflammatory processes. It plays a pro-inflammatory
role in rheumatoid arthritis synoviocytes through mitogen-
activated protein kinase, Janus kinase/signal transducers
and activators of transcription, and nuclear factor-kappa B
(NF-kB) signaling[9]; conversely, it has a protective role in
the heart through alleviating ischemia and reperfusion
injury in cardiomyocytes.[10]
A previous study on the role of FSTL1 in systemic vasculitis
reported an association between plasma FSTL1 and
coronary artery aneurysm in patients with Kawasaki
disease.[11] Given the earlier findings and the role of FSTL1
in the inflammatory processes, it can be theoretically
assumed that serum FSTL1 may predict the current AAV-
specific indices. However, there is no study regarding the
clinical implication of serum FSTL1 for predicting those
indices to date. Therefore, in this study, we recorded the
current BVAS, FFS, VDI, SF-36 PCS, and SF-36 MCS at
the time of blood sampling, and measured FSTL1 in the
stored serum. Furthermore, we investigated whether serum
FSTL1 could predict the current AAV-specific indices in
patients who were recently diagnosed with AAV.Methods
Ethical approval
This studywas approved by the Institutional Review Board
of Severance Hospital (No. 4-2016-0901) and written
informed consent was obtained from the patients at the
time of blood sampling.Patients
We randomly selected 74 patients with AAV, who had
been enrolled in the Severance hospital ANCA-associated
vasculitides cohort, a prospective and observational cohort
of Korean patients with AAV, from November 2016 to
January 2020, and included them in this study. All patients
were initially diagnosed with AAV at the Division of
Rheumatology, Department of Internal Medicine, Yonsei
University College of Medicine and Severance Hospital
and they met both classification criteria, namely the 2007
European Medicines Agency Algorithms for AAV and
Polyarteritis Nodosa and the 2012 revised International
Chapel Hill Consensus Conference Nomenclature of
Vasculitides.[1,2] AAV patients with serious medical1169conditions, such as serious infections, malignancies, or
other accompanying systemic vasculitides, were excluded
from this study.Clinical and laboratory data
All clinical data, including age, gender, AAV subtypes, and
clinical manifestations based on BVAS and laboratory
data, were recorded. AAV-specific indices including BVAS,
FFS, VDI, SF-36 PCS, and SF-36 MCS were also recorded.
ANCA was measured on the same day. Acute-phase
reactants, namely the erythrocyte sedimentation rate (ESR)
and C-reactive protein (CRP) level, were also measured.
Myeloperoxidase (MPO)-ANCA and proteinase 3 (PR3)-
ANCA were measured using the novel anchor-coated
highly sensitive Phadia ELiA (Thermo Fisher Scientific/
Phadia, Freiburg, Germany) and human native antigens,
on the Phadia250 analyzer (Thermo Fisher Scientific/
Phadia). In this study, we used immunoassays as the
primary screening method for ANCA; however, when
patients were found to be negative for ANCA by an
antigen-specific assay but positive by an indirect immuno-
fluorescence assay, they were considered to have MPO-
ANCA or PR3-ANCA when AAV was strongly suspected
based on the clinical and laboratory features.[12] The
currently administered AAV-related medications were also
reviewed.Blood samples and measurement of serum FSTL1
On the same visit day, whole blood was obtained from
each AAV patients on patients’ consent. Sera is immedi-
ately isolated from whole blood and stored at 80°C.
FSTL1 concentration in stored sera was determined using
enzyme-linked immunosorbent assay kits (Abcam, Cam-
bridge, UK) according to the manufacturer’s instructions.
The sensitivity was <10 pg/mL and intra- and inter-assay
coefficients of variation were 4.2% to 6.4% and 6.4% to
7.8%, respectively.Definition of low SF-36
We defined the lowest tertile of SF-36 PCS and SF-36MCS
as the current low SF-36 PCS and SF-36MCS, respectively.
The cutoff values (the upper limit of the lowest tertile) of
the current low SF-36 PCS and SF-36 MCS were
determined as 38.4 and 46.8, respectively.Statistical analyses
All statistical analyses were performed using SPSS software
(version 25 forWindows; IBMCorp., Armonk, NY, USA).
Continuous variables are expressed as medians with
interquartile range (IQR), whereas categorical variables
are expressed as numbers (percentage). The standardized
correlation coefficient was obtained by the multivariable
linear regression analysis using variables with statistical
significance in the univariable linear regression analysis.
The optimal cutoffs of serum FSTL1 for the current low SF-
36 PCS and SF-36 MCS were extrapolated by conducting
the receiver operator characteristic (ROC) curve and
selecting the maximized sum of sensitivity and specificity.
The relative risk (RR) was analyzed using the contingency
Table 1: Characteristics of 74 AAV patients at blood sampling.
Variables Values
Demographic data
Chinese Medical Journal 2021;134(10) www.cmj.orgtables and the chi-square test. Significant differences in
serum FSTL1 between the presence and absence of each
clinical manifestation based on BVAS items were com-
pared using the Mann-Whitney test. P values< 0.05 were
considered statistically significant.Age (years) 62.5 (20.0)
Female, n (%) 41 (55.4)




ANCA positivity, n (%)
MPO-ANCA (or P-ANCA) positivity 44 (59.5)
PR3-ANCA (or C-ANCA) positivity 6 (8.1)
Both ANCAs positivity 3 (4.1)
ANCA negative 27 (36.5)
Clinical manifestations based on BVAS items, n (%)
Generalised symptoms 24 (32.4)
Skin 8 (10.8)
Mucous membrane and eyes 2 (2.7)





Nervous system 20 (27.0)Results
Characteristics
The median age of patients was 62.5 (IQR = 20.0) years,
and 41 patients were women. Of 74 patients, 35 were
classified asMPA, 24with GPA, and 15with EGPA. Forty-
four patients were detected with MPO-ANCA (or P-
ANCA), whereas only six were positive for PR3-ANCA (or
C-ANCA). The most frequently affected organ was the
lung (58.1%), followed by the kidney (52.7%) and the ear,
nose, and throat (44.6%). The median SF-36 PCS, SF-
MCS, BVAS, FFS, and VDI were 50.8, 54.2, 7.5, 1.0, and
3.0, respectively. The median ESR and CRP levels were
30.5 mm/h and 2.9 mg/L, respectively. The median serum
FSTL1 was 879.1 pg/mL. At sampling, 62 patients
(83.8%) received glucocorticoid and the most frequently
administered immunosuppressive drug was azathioprine
(39.2%) followed by cyclophosphamide (8.1%). Ritux-
imab was provided to one patient (1.4%) [Table 1].AAV-specific indices
SF-36 PCS 50.8 (32.3)





ESR (mm/h) 30.5 (49.0)
CRP (mg/L) 2.9 (12.2)
Serum FSTL1 (pg/mL) 879.1 (685.7)
AAV-related medications currently administered, n (%)
Glucocorticoid 62 (83.8)Correlation analysis
Serum FSTL1 did not seem to be affected by age. Among
the current AAV-specific indices, serum FSTL1 was
significantly correlated with SF-36 PCS (r=0.374,
P= 0.001) and SF-36 MCS (r=0.377, P= 0.001);
however, it was not correlated with BVAS, FFS, and
VDI. Among the current acute-phase reactants, serum
FSTL1 was positively correlated with CRP level (r= 0.307,
P= 0.008); however, it was not correlated with ESR
[Figure 1].Cyclophosphamide 6 (8.1)
Rituximab 1 (1.4)
Azathioprine 29 (39.2)
Mycophenolate mofetil 1 (1.4)
Tacrolimus 2 (2.7)
Methotrexate 3 (4.1)
Values are expressed as median (interquartile range [IQR]) or number
(percentage). AAV: Anti-neutrophil cytoplasmic antibody-associated
vasculitis; ANCA: Anti-neutrophil cytoplasmic antibody; BVAS: Birming-
ham vasculitis activity score; C: Cytoplasmic; CRP: C-reactive protein;
EGPA: Eosinophilic GPA; ESR: Erythrocyte sedimentation rate; FFS: Five-
factor score; FSTL1: Follistatin-related protein 1; GPA: Granulomatosis
with polyangiitis;MCS:Mental component summary;MPA:Microscopic
polyangiitis; MPO: Myeloperoxidase; P: Perinuclear; PCS: Physical
component summary; PR3: Proteinase 3; SF-36: The short-form 36-item
health survey; VDI: Vasculitis damage index.Linear regression analyses
Based on the current SF-36 PCS, in the univariable
analysis, BVAS (b=0.357), FFS (b=0.229), ESR
(b=0.272), CRP (b=0.484), and FSTL1 (b=0.374)
were significantly correlated with the current SF-36 PCS.
Furthermore, in the multivariable analysis, BVAS
(b=0.255, P= 0.024), CRP (b=0.430, P= 0.005),
and serum FSTL1 (b=0.266, P= 0.012) were indepen-
dently associated with the current SF-36 PCS. In addition,
based on the current SF-36 MCS, in the univariable
analysis, MPO-ANCA (or P-ANCA) (b=0.258), BVAS
(b=0.327), CRP (b=0.433), and serum FSTL1
(b=0.377) were significantly correlated with the current
SF-36 MCS. Furthermore, in the multivariable analysis,
BVAS (b=0.234, P= 0.031), CRP (b=0.229,
P= 0.048), and serum FSTL1 (b=0.296, P= 0.006)
exhibited an independent association with the current SF-
36 MCS [Table 2].Cutoff value of serum FSTL1 for the current low SF-36
The optimal cutoff value of serum FSTL1 for predicting the
current low SF-36 PCS (SF-36 PCS 38.4) was evaluated1170as 779.8 pg/mL using the ROC curve (area 0.727, 95%
confidence interval [CI] 0.608, 0.846). Patients with AAV
were divided into two groups based on the cutoff value of
serum FSTL1; patients with serum FSTL1 ≥779.8 pg/mL
exhibited a significantly higher risk of having the current
low SF-36 PCS than those with FSTL1 <779.8 pg/mL (RR
7.583, 95% CI 2.004, 28.698) [Figure 2]. In addition, the
Figure 1: Serum FSTL1 was significantly correlated with SF-36 PCS, SF-36 MCS, and CRP, but not with age, BVAS, FFS, ESR, and VDI. BVAS: Birmingham vasculitis activity score; CRP:
C-reactive protein; ESR: Erythrocyte sedimentation rate; FFS: Five-factor score; FSTL1: Follistatin-like 1; MCS: Mental component summary; PCS: Physical component summary; SF-36: The
Korean version of the short-form 36-item health survey; VDI: Vasculitis damage index.
Table 2: Linear regression analyses of variables based on SF-36 PCS and SF-36 MCS in AAV patients.
Univariable analysis Multivariable analysis
Items Standardized b 95% CI P values Standardized b 95% CI P values
Based on SF-36 PCS
Age 0.142 0.576, 0.139 0.227
MPO-ANCA (or P-ANCA) 0.082 7.460, 3.577 0.485
PR3-ANCA (or C-ANCA) 0.098 7.533, 18.460 0.405
BVAS 0.357 1.620, 0.386 0.002 –0.255 –1.336, –0.095 0.024
FFS 0.229 10.631, 0.014 0.049 –0.067 –6.444, 3.346 0.530
VDI 0.006 2.766, 2.915 0.958
ESR 0.272 0.308, 0.028 0.019 0.180 –0.065, 0.288 0.212
CRP 0.484 0.372,0.150 <0.001 –0.430 –0.391, –0.073 0.005
FSTL1 0.374 0.010, 0.003 0.001 –0.266 –0.008, –0.001 0.012
Based on SF-36 MCS
Age 0.162 0.501, 0.089 0.168
MPO-ANCA (or P-ANCA) 0.258 9.468, 0.613 0.026 –0.133 –6.595, 1.419 0.202
PR3-ANCA (or C-ANCA) 0.076 7.261, 14.296 0.517
BVAS 0.327 1.278, 0.245 0.004 –0.234 –1.039, –0.050 0.031
FFS 0.220 8.631, 0.177 0.060
VDI 0.017 2.522, 2.180 0.885
ESR 0.215 0.228, 0.007 0.066
CRP 0.433 0.288, 0.099 <0.001 –0.229 –0.204, –0.001 0.048
FSTL1 0.377 0.009, 0.002 0.001 –0.296 –0.007, –0.001 0.006
AAV: Anti-neutrophil cytoplasmic antibody-associated vasculitis; ANCA: Anti-neutrophil cytoplasmic antibody; BVAS: Birmingham vasculitis activity
score; C: Cytoplasmic; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; FFS: Five-factor score; FSTL1: Follistatin-related protein 1; MCS:
Mental component summary;MPO:Myeloperoxidase; P: Perinuclear; PCS: Physical component summary; PR3: Proteinase 3; SF-36: The short-form 36-
item health survey; VDI: Vasculitis damage index.
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current low SF-36 MCS (SF-36 MCS 46.8) was
determined as 841.6 pg/mL using the ROC curve (area
0.754, 95% CI 0.639, 0.869). Patients with AAV were
divided into two according to the cutoff value of serum
FSTL1; patients with serum FSTL1 ≥841.6 pg/mL
exhibited a significantly higher risk of having the current
low SF-36 MCS than those with FSTL1 <841.6 pg/mL
(RR 6.200, 95% CI 1.986, 19.360) [Figure 3].1171Discussion
In this study, we investigated whether serum FSTL1 could
predict the current AAV-specific indices including BVAS,
FFS, VDI, SF-36 PCS, and SF-36 MCS, in 74 patients who
were recently diagnosed with AAV; consequently, we had
four observations. First, in the univariate correlation
analysis, serum FSTL1 was significantly correlated with
SF-36 PCS (r=0.374), SF-36 MCS (r=0.377), and
CRP (r= 0.307), but it was not at all correlated with
Figure 2: The cutoff value of serum FSTL1 for predicting the current low SF-36 PCS (SF-36 PCS 38.4) was set as 779.8 pg/mL. Patients with serum FSTL1 ≥779.8 pg/mL exhibited a
significantly higher risk of having the current low SF-36 PCS than those with FSTL1<779.8 pg/mL. CI: Confidence interval; FSTL1: Follistatin-like 1; PCS: Physical component summary; RR:
Relative risk; SF-36: The Korean version of the short-form 36-item health survey.
Figure 3: The cutoff value of serum FSTL1 for assessing the current low SF-36 MCS (SF-36 MCS 46.8) was set as 841.6 pg/mL. Patients with serum FSTL1 ≥841.6 pg/mL exhibited a
significantly higher risk of having the current low SF-36 MCS than those with FSTL1<841.6 pg/mL. CI: Confidence interval; FSTL1: Follistatin-like 1; MCS: Mental component summary; RR:
Relative risk; SF-36: The Korean version of the short-form 36-item health survey.
Chinese Medical Journal 2021;134(10) www.cmj.orgBVAS, FFS, and VDI. Second, in the multivariable linear
regression analysis, serum FSTL1 was independently
associated with both SF-36 PCS (b=0.266) and SF-36
MCS (b=0.296). Third, AAV patients with serum
FSTL1 ≥779.8 pg/mL exhibited a significantly higher risk
of having the current low SF-36 PCS than those with
FSTL1 <779.8 pg/mL (RR 7.583). Fourth, AAV patients
with serum FSTL1 ≥841.6 pg/mL exhibited a significantly
higher risk of having the current low SF-36 MCS than
those with FSTL1 <841.6 pg/mL (RR 6.200).
FSTL1 plays a dual and opposing regulatory role in the
process of inflammation. As a pro-inflammatory role, it
binds to pro-inflammatory receptors, such as toll-like
receptor 4, accelerating the expression of pro-inflammato-
ry cytokines through extracellular signal-regulated kinases
1/2, c-Jun N-terminal kinase, and NF-kB pathways.[9,13]
Among increased pro-inflammatory cytokines, tumor
necrosis factor-a, and interferon-g directly augment the
expression and secretion of FSTL1, whereas interleukin
(IL)-1b indirectly enhances its expression through the NF-
kB pathway, leading to the formation of a positive
feedback loop.[14] In addition, FSTL1 may enhance the
proliferation and polarization of immune cells, particular-1172ly, tissue macrophages, and aggravates inflammation.[15]
As an anti-inflammatory role, FSTL1 also binds to anti-
inflammatory receptors, such as disco interacting protein 2
homolog A, resulting in downregulation of metallopro-
teinase 2, 3, and 13,[9] as well as stimulation of the
transforming growth factor b/Smad signaling pathway.[16]
In this study, there was no significant correlation between
serum FSTL1 and BVAS, although both serum FSTL1 and
BVAS exhibited significant correlations with CRP (serum
FSTL1 and CRP: r= 0.307, P = 0.008, and BVAS and
CRP: r= 0.336, P= 0.003). We attempted to understand
the reason through the following two different mecha-
nisms. First, for the pro-inflammatory effect, serum FSTL1
may gradually increase BVAS and CRP production in the
liver through increased IL-6.[17] Second, for the anti-
inflammatory effect, serum FSTL1 may gradually decrease
BVAS but without affecting CRP production in the liver,
through increased IL-6.[16,18] In theory, serum FSTL1 is
positively correlated with the current BVAS as well as CRP
while exhibiting the pro-inflammatory effect. In contrast,
serum FSTL1 is negatively correlated with the current
BVAS but not with CRP, while exhibiting the anti-
inflammatory effect. Therefore, the discrepancies in the
Chinese Medical Journal 2021;134(10) www.cmj.orgcorrelations of serum FSTL1 with BVAS and CRP can be
explained by these dual effects of serum FSTL1 in the
inflammatory processes.
We speculated on why serum FSTL1 was significantly
associated with both SF-36 PCS and SF-36 MCS rather
than BVAS and VDI. The approach to the answer should
start from the temporal concept of the three indicators. A
VDI reflects organ damage resulting from the inflammato-
ry burden accumulated over a long period of time[5]; it may
not have shown a significant correlation with FSTL1
because the rate of fibrosis is higher than that of chronic
inflammation.[19] Since BVAS is associated with relatively
the sub-acute or acute inflammatory processes,[3] the
aforementioned dual and opposing regulatory role of
FSTL1 would interfere with and dilute the significant
correlation between BVAS and FSTL1. On the other hand,
since both SF-36 PCS and SF-36 MCS are relatively
associated with the chronic inflammatory processes rather
than acute or sub-acute ones,[6] the pro-inflammatory role
of FSTL1 may surpass its anti-inflammatory role, which
may have enabled the correlation between serum FSTL1
and either SF-36 PCS, or SF-36 MCS.
This study describes a method to obtain the cutoff value of
serum FSTL1 for predicting the current low SF-36 PCS and
SF-36 MCS. Regarding the clinical significance of determin-
ing the cutoff value of serumFSTL1 for predicting the current
lowSF-36PCSandSF-36MCS,bothare themostwidelyused
self-reported indices for assessing health-related quality of life
(HRQOL) as frequently as the health assessment question-
naire scores.[6,20] Additionally, they are currently used for
predicting the functional status, which is considered as an
important therapeutic goal as predicting the current activity
and organ damage in patients with AAV. Therefore, clinical
trials enrolling AAV patients have included SF-36 PCS and
SF-36 MCS as the essential indicators for determining the
effectiveness of therapeutic drugs to date.[21,22] Nevertheless,
in a real clinical setting, it is not easy to complete the SF-36
form at every visit for the following individuals: elderly
patients complaining of decreased vision, patients suffering
from cognitive dysfunction and not accompanied by a
caregiver, and patients treated in the intensive care unit due to
serious organ damage. If there is an indicator that predicts the
current low SF-36 PCS and SF-36 MCS, such as serum
FSTL1, a qualitative evaluation, but not a quantitative
evaluation of the functional status of AAVmay be possible in
these patients.
Although there was no significant correlation between
serum FSTL1 and the current BVAS, we wonder whether
serum FSTL1 may differ according to the presence of each
clinical manifestation based on BVAS items,[3] and
compared serum FSTL1 in the presence and absence of
each clinical manifestation. Among nine clinical manifes-
tations based on BVAS items, serum FSTL1 tended to differ
according to the manifestation of heart disease. Given that
a previous study reported the predictive potential of
plasma FSTL1 for coronary artery aneurysm in patients
with Kawasaki disease, we compared the median serum
FSTL1 between the two groups.[11] However, the median
serum FSTL1 was much lower in patients with the
manifestation of heart disease than in patients without1173the manifestation (655.2 vs. 963.0 pg/mL), although the
difference was not statistically significant (P= 0.090).
Furthermore, among four AAV patients with heart
involvement, three presented pericarditis and one exhib-
ited myocarditis without the evidence of coronary arterial
involvement. Together, these results suggest that the
clinical implication of FSTL1 in systemic vasculitides
may vary depending on the size of the affected vessel and
the entity of each vasculitis.[1]
To the best of our knowledge, the clinical implications of
serum FSTL1 in AAV have never been investigated
previously. Thus, this is the first pilot study to reveal that
serum FSTL1 was significantly and independently corre-
lated with the current SF-36 PCS and SF-36 MCS, but not
with BVAS, FFS, and VDI in AAV patients. Moreover, we
described the method to obtain the cutoff values of serum
FSTL1 for predicting the current low SF-36 PCS and SF-36
MCS (the lowest tertile of each SF-36) and reported the RR
associated with more than one cutoff values of serum
FSTL1 for predicting the current low SF-36.
However, our study has several limitations. The number of
AAV patients was not large enough to represent all AAV
patients inKorea or to strengthen the reliability of our results.
Due to the cross-sectional study design, it was impossible to
analyze the dynamic correlation between serum FSTL1 and
SF-36 at different time points. The measurement of pro-
inflammatory cytokines couldhave supportedourhypothesis
pertaining to the correlation of serum FSTL1with BVAS and
SF-36, but it was not measured in this study. Also, we could
not include positive controls in this study owing to a small
number of age- and gender-matched positive controls.
Moreover, it might be a correlation coefficient that can be
judged fair if it ranges from 0.3 to 0.5,[23] however, the
correlation coefficients of FSTL1 with SF-36 PCS and SF-36
MCS were not high enough to support its potential as a
biomarker for estimating the functional status of AAV.
Therefore, although SF-36 PCS and MCS are indicators
related to quality-of-life,which aremixtures of subjective and
objective contents, a higher correlation coefficient should be
validated by a larger number of AAV patients. We believe
that the findings of this pilot study revealing the clinical
implications of serum FSTL1 in AAV for the first time will
have an impact on clinical practice. Furthermore, we expect
that future prospective studies including a larger population,
analyses of paired blood samples, and clinical data will
provide valuable information on the dynamic clinical
significance as well as the potential of serum FSTL1 for
predicting prognosis in AAV patients.
We conclude that serum FSTL1 could predict the current
both SF-36 PCS and MCS in AAV patients. We suggest
that serum FSTL1 may be used for estimating the current
functional status of AAV in patients who have difficulties
in completing the SF-36 forms, not only for assessing
HRQOL but also for evaluating the achievement of the
therapeutic goals.Funding
This study was supported by a faculty research grant from
the Yonsei University College of Medicine (No. 6-2019-
Chinese Medical Journal 2021;134(10) www.cmj.org0184) and a grant from the Korea Health Technology
R&D Project through the Korea Health Industry Devel-
opment Institute, funded by the Ministry of Health and
Welfare, Republic of Korea (No. HI14C1324).Conflicts of interest
None.References
1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al.
2012 Revised International Chapel Hill Consensus conference
nomenclature of vasculitides. Arthritis Rheum 2013;65:1–11. doi:
10.1002/art.37715.
2. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W,
et al. Development and validation of a consensusmethodology for the
classification of the ANCA-associated vasculitides and polyarteritis
nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222–
227. doi: 10.1136/ard.2006.054593.
3. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S,
et al. Modification and validation of the Birmingham Vasculitis
Activity Score (version 3). Ann Rheum Dis 2009;68:1827–1832. doi:
10.1136/ard.2008.101279.
4. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin
P. French Vasculitis Study Group (FVSG). The five-factor score
revisited: assessment of prognoses of systemic necrotizing vasculitides
based on the French Vasculitis StudyGroup (FVSG) cohort.Medicine
(Baltimore) 2011;90:19–27. doi: 10.1097/MD.0b013e318205a4c6.
5. Bhamra K, Luqmani R. Damage assessment in ANCA-associated
vasculitis. Curr Rheumatol Rep 2012;14:494–500. doi: 10.1007/
s11926-012-0291-1.
6. HanC-W, Lee E-J, Iwaya T, KataokaH, KohzukiM.Development of
the Korean version of short-form 36-item health survey: health
related QOL of healthy elderly people and elderly patients in Korea.
Tohoku J Exp Med 2004;203:189–194. doi: 10.1620/tjem.203.189.
7. Geng Y, Dong Y, YuM, Zhang L, Yan X, Sun J, et al. Follistatin-like
1 (Fstl1) is a bone morphogenetic protein (BMP) 4 signaling
antagonist in controlling mouse lung development. Proc Natl Acad
Sci U S A 2011;108:7058–7063. doi: 10.1073/pnas.1007293108.
8. Sylva M, Li VSW, Buffing AAA, van Es JH, van den BornM, van der
Velden S, et al. The BMP antagonist follistatin-like 1 is required for
skeletal and lung organogenesis. PLoS One 2011;6:e22616. doi:
10.1371/journal.pone.0022616.
9. Ni S, Li C, Xu N, Liu X, Wang W, Chen W, et al. Follistatin-like
protein 1 induction of matrix metalloproteinase 1, 3 and 13 gene
expression in rheumatoid arthritis synoviocytes requires MAPK,
JAK/STAT3 andNF-kB pathways. J Cell Physiol 2018;234:454–463.
doi: 10.1002/jcp.26580.
10. Yang W, Duan Q, Zhu X, Tao K, Dong A. Follistatin-like 1
attenuates ischemia/reperfusion injury in cardiomyocytes via regula-
tion of autophagy. Biomed Res Int 2019;2019:9537382. doi:
10.1155/2019/9537382.
11. Gorelik M, Wilson DC, Cloonan YK, Shulman ST, Hirsch R. Plasma
follistatin-likeprotein1 is elevated inKawasakidiseaseandmaypredict1174coronary artery aneurysm formation. J Pediatr 2012;161:116–119.
doi: 10.1016/j.jpeds.2012.01.011.
12. McAdoo SP,Medjeral-ThomasN,Gopaluni S, TannaA,MansfieldN,
Galliford J, et al. Long-term follow-up of a combined rituximab and
cyclophosphamide regimen in renal anti-neutrophil cytoplasm anti-
body-associated vasculitis. Nephrol Dial Transplant 2019;34:63–73.
doi: 10.1093/ndt/gfx378.
13. Chen L, Liu Z. Downregulation of FSTL-1 attenuates the inflamma-
tion injury during Streptococcus pneumoniae infection by inhibiting
the NLRP3 and TLR4/NF-kB signaling pathway. Mol Med Rep
2019;20:5345–5352. doi: 10.3892/mmr.2019.10752.
14. Liu Y, Wei J, Zhao Y, Zhang Y, Han Y, Chen B, et al. Follistatin-like
protein 1 promotes inflammatory reactions in nucleus pulposus cells
by interacting with the MAPK and NF-kB signaling pathways.
Oncotarget 2017;8:43023–43034. doi: 10.18632/oncotarget.17400.
15. Li G, Ren H, Wu X, Hu Q, Hong Z, Wang G, et al. Follistatin like
protein-1 modulates macrophage polarization and aggravates
dextran sodium sulfate-induced colitis. Int Immunopharmacol
2020;83:106456. doi: 10.1016/j.intimp.2020.106456.
16. ZhengX,QiC,ZhangS,FangY,NingW.TGF-b1 inducesFstl1via the
Smad3-c-Jun pathway in lung fibroblasts. Am J Physiol Lung CellMol
Physiol 2017;313:L240–L251. doi: 10.1152/ajplung.00523.2016.
17. Slaats J, TenOever J, van deVeerdonk FL,NeteaMG. IL-1b/IL-6/CRP
and IL-18/ferritin: distinct inflammatory programs in infections. PLoS
Pathog 2016;12:e1005973. doi: 10.1371/journal.ppat.1005973.
18. Hu PF, Ma CY, Sun FF, Chen WP, Wu LD. Follistatin-like protein 1
(FSTL1) promotes chondrocyte expression of matrix metalloprotei-
nase and inflammatory factors via the NF-kB pathway. J Cell Mol
Med 2019;23:2230–2237. doi: 10.1111/jcmm.14155.
19. Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic
autoantibody-mediated disease. Nat Rev Rheumatol 2014;10:463–
473. doi: 10.1038/nrrheum.2014.103.
20. Kim HL, Kim D, Jang EJ, Lee MY, Song HJ, Park SY, et al. Mapping
health assessment questionnaire disability index (HAQ-DI) score,
pain visual analog scale (VAS), and disease activity score in 28 joints
(DAS28) onto the EuroQol-5D (EQ-5D) utility score with the
KORean Observational study Network for Arthritis (KORONA)
registry data. Rheumatol Int 2016;36:505–513. doi: 10.1007/
s00296-016-3427-1.
21. Pugnet G, Pagnoux C, Terrier B, Perrodeau E, Puéchal X, Karras A,
et al. Rituximab vs azathioprine for ANCA-associated vasculitis
maintenance therapy: impact on global disability and health-related
quality of life. Clin Exp Rheumatol 2016;34:S54–S59.
22. Suka M, Hayashi T, Kobayashi S, Ito S, Yumura W, Ozaki S.
Improvement in health-related quality of life in MPO-ANCA-
associated vasculitis patients treated with cyclophosphamide plus
prednisolone: an analysis of 18 months of follow-up data from the
JMAAV study. Mod Rheumatol 2012;22:877–884. doi: 10.1007/
s10165-012-0602-4.
23. Akoglu H. User’s guide to correlation coefficients. Turk J EmergMed
2018;18:91–93. doi: 10.1016/j.tjem.2018.08.001.
How to cite this article: Yoon T, Ahn SS, Pyo JY, Song JJ, Park YB,
Lee SW. Association between follistatin-related protein 1 and the
functional status of patients with anti-neutrophil cytoplasmic antibody-
associated vasculitis. Chin Med J 2021;134:1168–1174. doi: 10.1097/
CM9.0000000000001454
